Cns Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
CNS Pharmaceuticals, Inc. director Faith Charles has granted a power of attorney to Rami Levin and Steve O'Loughlin for SEC filing compliance.
NASDAQ
CNS Pharmaceuticals' Chief Technology Officer, Eric Faulkner, received a grant of 9,500 Restricted Stock Units as part of his employment compensation.
NASDAQ
CNS Pharmaceuticals, Inc. Chief Financial Officer Steve O'Loughlin received a grant of 9,500 restricted stock units as part of his employment compensation.
NASDAQ
CNS Pharmaceuticals' CEO and President, Rami Levin, was granted 19,000 restricted stock units, vesting over several years, as part of his employment.
NASDAQ
CNS Pharmaceuticals Director Jeffry R. Keyes was granted 1,517 stock options with an exercise price of $12.48, vesting quarterly over one year.
NASDAQ
CNS Pharmaceuticals Director Bettina M. Cockroft was granted 1,517 stock options with an exercise price of $12.48, vesting quarterly over one year.
NASDAQ
CNS Pharmaceuticals, Inc. CEO John M. Climaco was granted options to purchase 9,761 shares of common stock with an exercise price of $30.
NASDAQ
CNS Pharmaceuticals Director Amy Mahery was granted options to purchase 1,517 shares of common stock at an exercise price of $12.48, vesting quarterly.
NASDAQ
CNS Pharmaceuticals, Inc. director Faith L. Charles was granted 1,517 stock options with an exercise price of $12.48, vesting quarterly over one year.
NASDAQ
CNS Pharmaceuticals director Jerzy Gumulka received options to purchase 1,517 shares of common stock at an exercise price of $12.48, vesting quarterly over one year.
NASDAQ
CNS Pharmaceuticals' CFO Christopher Downs received 4,881 stock options with a $30 exercise price, vesting over 18 months.
NASDAQ
Cortice Biosciences, Inc. is no longer subject to Section 16 reporting requirements due to an increase in the number of outstanding shares of CNS Pharmaceuticals, Inc.
NASDAQ
Director Amy Mahery acquired stock options and restricted stock units in CNS Pharmaceuticals, Inc. related to board service.
NASDAQ
Director Jeffry R. Keyes acquired stock options and restricted stock units in CNS Pharmaceuticals, Inc. related to his board service.
NASDAQ
Director Jerzy Gumulka reports acquisition of options and restricted stock units in CNS Pharmaceuticals (CNSP) related to board service.
NASDAQ
Director Carl Anthony Evans reports acquisition of stock options and restricted stock units in CNS Pharmaceuticals.
NASDAQ
Christopher Downs, CFO of CNS Pharmaceuticals, reports acquisition of options and restricted stock units in company stock.
NASDAQ
Bettina M. Cockroft, a director at CNS Pharmaceuticals, acquired stock options and restricted stock units on April 8, 2024, related to her board service.
NASDAQ
CEO John M. Climaco acquired options to purchase 83,000 shares and 83,000 restricted stock units of CNS Pharmaceuticals on April 8, 2024.
NASDAQ
Director Charles Faith L. acquired options and restricted stock units in CNS Pharmaceuticals, Inc. on April 8, 2024.